Article

Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines

2021-02-02

Abstract excerpt

Recently, the emerged and rapidly spreading SARS-CoV-2 variant of concern (VOC) 501Y.V2 with 10 amino acids in spike protein were found to escape host immunity induced by infection or vaccination. Global concerns have been raised for its potential to affect vaccine efficacy. Here, we evaluated the neutralization activities of two vaccines developed in China against 501Y.V2. One is licensed inactivated vaccine BBIB...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 598867ee-fc3c-5631-9ee2-5ba39ab1d7ff
DOI: 10.1101/2021.02.01.429069

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccinesDOI 10.1101/2021.02.01.429069Read

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1Semantic proximity Read

Incorporation of Sars-Cov-2 Spike Ntd to Rbd-Based Vaccine Improves Immunity and Protection Against Viral VariantsSemantic proximity Read

Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.Semantic proximity Read

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variantsSemantic proximity Read

Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human seraSemantic proximity Read

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccinationSemantic proximity Read

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2Semantic proximity Read

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.Semantic proximity Read

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variantSemantic proximity Read

Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concernSemantic proximity Read

Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccineSemantic proximity Read

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesSemantic proximity Read